SCHEMBL21501949

SCHEMBL21501949

O=C(Nc1cncc(O)c1)OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.65
MGLL Q99685 2/20 0.58
ROCK2 O75116 2/20 0.54
P2RX7 Q99572 1/20 0.52
MAPT P10636 3/20 0.52
ENPP2 Q13822 2/20 0.52
NPC1 O15118 2/20 0.52
ALDH1A1 P00352 2/20 0.52
TP53 P04637 2/20 0.52
RAB9A P51151 2/20 0.52
TSHR P16473 1/20 0.52
ATM Q13315 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NAMPT P43490 2/20 0.51
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 1/20 0.50
KDM1A O60341 1/20 0.49
MAOA P21397 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1455112 0.86 POLB (0.62) POLBMGLLROCK2P2RX7MAPT
SCHEMBL3586577 0.86 POLB (0.62) POLBMGLLROCK2P2RX7MAPT
SCHEMBL1454511 0.86 POLB (0.62) POLBMGLLROCK2P2RX7MAPT
SCHEMBL29957457 0.84 POLB (0.59) POLBMGLLROCK2P2RX7MAPT
SCHEMBL20605796 0.84 POLB (0.59) POLBMGLLROCK2P2RX7MAPT
SCHEMBL19993034 0.84 POLB (0.70) POLBMGLLROCK2P2RX7MAPT
SCHEMBL655257 0.83 MGLL (0.66) POLBMGLLROCK2MAPTENPP2
SCHEMBL9459601 0.83 MGLL (0.66) POLBMGLLROCK2MAPTENPP2
SCHEMBL14923524 0.82 POLB (0.56) POLBMGLLROCK2P2RX7MAPT
SCHEMBL968903 0.81 POLB (0.71) POLBMGLLROCK2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11382971-B2 Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant TSINGHUA UNIVERSITY (CN) 2022-07-12 US disclosed
US-20190321465-A1 MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT TSINGHUA UNIVERSITY (CN) 2019-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190321465-A1 MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT GGPS1, HMGCR, COASY POLB 1608/4885MGLL 260/4885ROCK2 1229/4885
US-11382971-B2 Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant GGPS1, HMGCR, COASY POLB 1607/4885MGLL 253/4885ROCK2 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.